– Presented data for first CELsignia Pathway Activity Test for ovarian cancer at AACR Annual Meeting –
– Expect to announce new clinical trial collaborations with pharmaceutical companies and trial sponsors by the end of 2020 –
– Cash burn rate steady –
– Cash and Cash Equivalents of $15.4 million as of June 30, 2020, which is expected to support operations through 2021 –
– Conference Call on Monday, August 10th at 4:30pm (ET) –
MINNEAPOLIS, MN / ACCESSWIRE / August 10, 2020 / Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into
